Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.~2. Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of age, inclusive, at screening.~Exclusion Criteria:~1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.~2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI.~3. History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Q203 (Type: EXPERIMENTAL): Q203 tablets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).